AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

Contributed by: Business Wire

Logo

Tags

Research

Infectious Diseases

Clinical Trials

Cardiology

Other Health

Biotechnology

Pharmaceutical

Health

Science

Oncology

2030 Total Revenue Forecast

More Like This

AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

PR Newswire associated0

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

PR Newswire associated0

Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance

PR Newswire associated0

Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Envision Energy Announces Collaboration with Five Global Healthcare Leaders to Unlock Renewable Energy in Davos